







Lab No. : DUR/14-05-2024/SR9109476

: ANKAN CHAKRABORTY

Age : 24 Y 3 M 7 D

Gender : M

Patient Name

: Newtown,Kolkata-700156 Lab Add.

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 14/May/2024 09:15AM

: 14/May/2024 06:48PM Report Date



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
-----------	--------	-------------------	------	--

PHOSPHORUS-INORGANIC, BLOOD, GEL 2.4-5.1 mg/dL mg/dL

SERUM (Method:Phosphomolybdate/UV)

*** End Of Report ***

MBBS MD (Biochemistry) Consultant Biochemist Reg No. WBMC 62456



 Patient Name
 : ANKAN CHAKRABORTY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 24 Y 3 M 7 D
 Collection Date
 : 14/May/2024 09:15AM

 Gender
 : M
 Report Date
 : 14/May/2024 04:28PM



DEPARTMENT OF BIOCHEMISTRY

		NT OF BIOCHEMISTRY	
Test Name	Result	Bio Ref. Interval	Unit
SGPT/ALT (Method:IFCC Kinetic Method)	<u>80</u>	< 41	U/L
CALCIUM,BLOOD (Method:ARSENAZO III)	9.80	8.6 - 10.2 mg/dl	mg/dL
CREATININE, BLOOD (Method:ENZYMATIC)	0.88	0.70 - 1.3 mg/dl	mg/dL
*BILIRUBIN (TOTAL) , GEL SERUM			
BILIRUBIN (TOTAL) (Method:Diazotized DCA Method)	0.70	< 1.2	mg/dL
UREA,BLOOD (Method:UREASE-GLDH)	23.2	12.8-42.8	mg/dl
ALKALINE PHOSPHATASE (Method:AMP)	55	53-128 U/L	U/L
BILIRUBIN (DIRECT) (Method:Diazotized DCA Method)	0.30	< 0.3	mg/dL
SODIUM,BLOOD (Method:ISE DIRECT)	140	136 - 145	mEq/L
POTASSIUM,BLOOD (Method:ISE DIRECT)	5.10	3.5 - 5.1	mEq/L
CHLORIDE,BLOOD (Method:ISE DIRECT)	105	98 - 107	mEq/L
GLUCOSE,FASTING (Method:GOD POD)	88	(70 - 110 mg/dl)	mg/dL
URIC ACID,BLOOD (Method:URICASE)	9.30	3.4 - 7.0	mg/dl
*TOTAL PROTEIN [BLOOD] ALB:GL	Ο ΒΑΤΙΟ		
TOTAL PROTEIN (Method:BIURET METHOD)	6.60	6.6 - 8.7	g/dL
ALBUMIN (Method:BCG)	4.2	3.5-5.2 g/dl	g/dl
GLOBULIN (Method:Calculated)	2.40	1.8-3.2	g/dl
AG Ratio (Method:Calculated)	1.75	1.0 - 2.5	
*LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:CHOD PAP Method)	166	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dL
TRIGLYCERIDES (Method:GPO-PAP)	<u>192</u>	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH > 500	mg/dL

Lab No. : DUR/14-05-2024/SR9109476 Page 2 of 11



 Patient Name
 : ANKAN CHAKRABORTY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 24 Y 3 M 7 D
 Collection Date
 : 14/May/2024 09:15AM

 Gender
 : M
 Report Date
 : 14/May/2024 04:28PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
HDL CHOLESTEROL (Method:DIRECT METHOD)	<u>35</u>	35.3-79.5 mg/dl	mg/dL
LDL CHOLESTEROL DIRECT (Method:Direct Method)	<u>107</u>	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Ven high: >=190 mg/dL	mg/dL
VLDL (Method:Calculated)	24	< 40 mg/dl	mg/dL
CHOL HDL Ratio (Method:Calculated)	<u>4.7</u>	LOW RISK 3.3-4.4 AVERAGE RIS 4.47-7.1 MODERATE RISK 7.1-11 HIGH RISK >11.0	
*THYROID PANEL (T3, T4, TSH) , GEL SI	ERUM		
T3-TOTAL (TRUIODOTHYRONINE)	1 40	0.9 - 2.2 na/ml	ng/ml

*THYROID PANEL (T3, T4, TSH), GEL SERUM			
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.40	0.9 - 2.2 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	11.0	5.5-16 microgram/dl	5.5-16 microgram/dl
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	1.3	0.5-4.7	μlU/mL

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER : 0.10 2.50 µ IU/mL

SECOND TRIMESTER : 0.20 3.00 µ IU/mL

THIRD TRIMESTER : 0.30 3.00 µ IU/mL

References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2.Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3.Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25];18:735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

SGOT/AST	35	< 40	U/L
(Method:IFCC Kinetic Method)			

*GLYCATED HAEMOGLOBIN (HBA1C),	EDTA WHOLE BLOOD	
GLYCATED HEMOGLOBIN (HBA1C)	5.4	***FOR BIOLOGICAL REFERENCE % INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***
HbA1c (IFCC)	35.0	mmol/mol

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Lab No.: DUR/14-05-2024/SR9109476 Page 3 of 11



Lab No. : DUR/14-05-2024/SR9109476 Lab Add. : CITY CENTER, DURGAPUR PIN-713

Patient Name : ANKAN CHAKRABORTY Ref Dr. : Dr.MEDICAL OFFICER : 24 Y 3 M 7 D **Collection Date** : 14/May/2024 09:15AM Age Gender : M Report Date : 14/May/2024 04:28PM



DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit

Analyzer used: BIORAD D-10

Method: HPLC

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be < 7% to help reduce microvascular complications and macrovascular disease. Action suggested > 8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B₁₂/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E/C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

- Chamberlain JJ. Phinehart AS. Shaefer CF. et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online
- Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. (2007;45(8):1077-1080.)

PDF Attached

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Page 4 of 11 Lab No. DUR/14-05-2024/SR9109476









Lab No. : DUR/14-05-2024/SR9109476

Patient Name : ANKAN CHAKRABORTY

Age : 24 Y 3 M 7 D

Gender : M

Lab Add. : Newtown,Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 14/May/2024 09:15AM

Report Date : 14/May/2024 07:17PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
-----------	--------	-------------------	------	--

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE 44.00 37-92 mg/dL mg/dL

(Method:URICASE)

*** End Of Report ***

Dr. SANCHAYAN SINHA MBBS, MD, DNB (BIOCHEMISTRY) CONSULTANT BIOCHEMIST Reg No. WBMC 63214

Lab No. : DUR/14-05-2024/SR9109476



 Patient Name
 : ANKAN CHAKRABORTY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 24 Y 3 M 7 D
 Collection Date
 : 14/May/2024 09:15AM

 Gender
 : M
 Report Date
 : 14/May/2024 04:28PM



DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit
1 COL HUITO	itoouit	Dio itoli liltoi vai	0

*CBC WITH PLATELET (THROMBOCYTE)	COUNT, EDTA WHOLE BLC	DOD	
HEMOGLOBIN (Method:PHOTOMETRIC)	14.0	13 - 17	g/dL
WBC (Method:DC detection method)	5.9	4 - 10	*10^3/µL
RBC (Method:DC detection method)	<u>6.79</u>	4.5 - 5.5	*10^6/µL
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy)	164	150 - 450*10^3	*10^3/µL
<u>DIFFERENTIAL COUNT</u>			
NEUTROPHILS (Method:Flowcytometry/Microscopy)	65	40 - 80 %	%
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	27	20 - 40 %	%
MONOCYTES (Method:Flowcytometry/Microscopy)	05	2 - 10 %	%
EOSINOPHILS (Method:Flowcytometry/Microscopy)	03	1 - 6 %	%
BASOPHILS (Method:Flowcytometry/Microscopy) CBC SUBGROUP	00	0-0.9%	%
HEMATOCRIT / PCV (Method:Calculated)	45.1	40 - 50 %	%
MCV (Method:Calculated)	<u>66.4</u>	83 - 101 fl	fl
MCH (Method:Calculated)	<u>20.7</u>	27 - 32 pg	pg
MCHC (Method:Calculated)	<u>31.1</u>	31.5-34.5 gm/dl	gm/dl
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	<u>15.3</u>	11.6-14%	%
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	16.7	8.3 - 25 fL	fL
MPV-MEAN PLATELET VOLUME (Method:Calculated)	9.2	7.5 - 11.5 fl	

*ESR (ERYTHROCYTE SEDIM	ENTATION RATE), EDTA WE	HOLE BLOOD		,
1stHour	07	0.00 - 20.00 mm/hr	mm/hr	
(Method:Westergren)				

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Lab No. : DUR/14-05-2024/SR9109476 Page 6 of 11









Lab No. : DUR/14-05-2024/SR9109476 Lab Add. : Newtown, Kolkata-700156

Patient Name : ANKAN CHAKRABORTY Ref Dr. : Dr.MEDICAL OFFICER : 24 Y 3 M 7 D **Collection Date** : 14/May/2024 09:15AM Age : 14/May/2024 06:59PM Gender : M Report Date



DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

(Method:Gel Card)

RH **POSITIVE**

(Method:Gel Card)

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

*** End Of Report ***

Dr. KAUSHIK DEY MD (PATHOLOGY) CONSULTANT PATHOLOGIST

Reg No. WBMC 66405

DUR/14-05-2024/SR9109476 Lab No.



Lab No. : DUR/14-05-2024/SR9109476

Patient Name : ANKAN CHAKRABORTY Ref Dr. : Dr.MEDICAL OFFICER

Age : 24 Y 3 M 7 D Collection Date

Gender : M Report Date : 14/May/2024 11:09AM



DEPARTMENT OF X-RAY

Lab Add.

X-RAY REPORT OF CHEST (PA)

FINDINGS:

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

IMPRESSION:

Normal study.

*** End Of Report ***

Dr Nidhi Sehgal DNB (Radio-diagnosis) Senior Consultant Radiologist

Lab No. : DUR/14-05-2024/SR9109476 Page 8 of 11



 Patient Name
 : ANKAN CHAKRABORTY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 24 Y 3 M 7 D
 Collection Date
 : 14/May/2024 09:15AM

 Gender
 : M
 Report Date
 : 14/May/2024 04:28PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

*URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION			
pН	5.5	4.6 - 8.0	
(Method:Dipstick (triple indicator method))	4.005	4.005 4.000	
SPECIFIC GRAVITY (Method:Dipstick (ion concentration method))	1.025	1.005 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
(Method:Dipstick (protein error of pH			
indicators)/Manual)			
GLUCOSE	NOT DETECTED	NOT DETECTED	
(Method:Dipstick(glucose-oxidase-peroxidase method)/Manual)			
KETONES (ACETOACETIC ACID,	NOT DETECTED	NOT DETECTED	
ACETONE)			
(Method:Dipstick (Legals test)/Manual)			
BLOOD	NOT DETECTED	NOT DETECTED	
(Method:Dipstick (pseudoperoxidase reaction)) BILIRUBIN	NEGATIVE	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)	NEGATIVE	NEGATIVE	
UROBILINOGEN	NEGATIVE	NEGATIVE	
(Method:Dipstick (diazonium ion reaction)/Manual)			
NITRITE	NEGATIVE	NEGATIVE	
(Method:Dipstick (Griess test))	NICOATIVE	NEC ATIVE	
LEUCOCYTE ESTERASE (Method:Dipstick (ester hydrolysis reaction))	NEGATIVE	NEGATIVE	
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	1-2	0-5	/hpf
(Method:Microscopy)			•
EPITHELIAL CELLS	0-1	0-5	/hpf
(Method:Microscopy)	NOT DETECTED	0.0	/laund
RED BLOOD CELLS (Method:Microscopy)	NOT DETECTED	0-2	/hpf
CAST	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)			
CRYSTALS	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)	NOT DETECTE	NOT DETECTED	
BACTERIA (Methodi Misroscopu)	NOT DETECTED	NOT DETECTED	
(Method:Microscopy) YEAST	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)	NOT DETECTED	NOT DETECTED	
·FJ/			

Note:

- $1. \ All \ urine \ samples \ are \ checked \ for \ adequacy \ and \ suitability \ before \ examination.$
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria

 Lab No. : DUR/14-05-2024/SR9109476 Page 9 of 11



 Patient Name
 : ANKAN CHAKRABORTY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 24 Y 3 M 7 D
 Collection Date
 : 14/May/2024 09:15AM

 Gender
 : M
 Report Date
 : 14/May/2024 04:28PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

and/or yeast in the urine.

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Lab No. : DUR/14-05-2024/SR9109476 Page 10 of 11



Lab No. : DUR/14-05-2024/SR9109476

Patient Name

: ANKAN CHAKRABORTY Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

Age : 24 Y 3 M 7 D Collection Date

Gender : M Report Date : 14/May/2024 02:31PM



DEPARTMENT OF CARDIOLOGY

DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

	:	Within normal limit.
IMPRESSION		Normal sinus rhythm.
T WAVE	21	Degree
QRS WAVE	29	Degree
P WAVE	34	Degree
AXIS		
QTC INTERVAL	378	Ms
QT INTERVAL	344	Ms
QRS DURATION	78	Ms
PR INTERVAL	136	Ms
HEART RATE	72	Врт
DATA		

Please correlate clinically

M.D.DipCard(PGDCC)Apollohospital,chennai CCEBDM.CCMH

Consultant Clinical Cardiologist

Lab No. : DUR/14-05-2024/SR9109476 Page 11 of 11



Arcofemi Healthcare Pvt Ltd

(Formerly known as Arcofemi Healthcare Ltd) F-701A, Lado Sarai, Mehrauli, New Delhi - 110030 Email: wellness@mediwheel.in, Website: www.mediwheel.in Tel: +91-11-41195959, Fax: +91-11-29523020

CIN: U24240DL2011PTC216307

MEDICAL FITNESS CERTIFICATE

(To be signed by a registered medical practitioner holding a Medical degree)

This is to certify that <u>Mr. Ankan Chakraborty</u> aged, <u>24yr</u>. Based on the examination, I certify that he is in good mental and physical health and it is free from any physical defects such as deafness, colour blindness, and any chronic or contagious diseases.

Place: Durgapur

Date: 14/05/2024

Dr. Nitesh Kumur MBBS BCMR 1293

Name & Signature of Medical officer